Genetic genealogy

Family Receives Unexpected Mother's Day Blessing: Virginia Higgins Ray Identified as Richland County's 1982 Jane Doe

Retrieved on: 
Tuesday, May 30, 2023

Richland County's State Hospital Jane Doe was a patient who died on February 15, 1982, after being admitted without a name due to a mental health crisis.

Key Points: 
  • Richland County's State Hospital Jane Doe was a patient who died on February 15, 1982, after being admitted without a name due to a mental health crisis.
  • In spite of an exhaustive campaign to determine her identity at the time, she remained unidentified for more than four decades.
  • The woman has now been identified as Virginia Clyde Higgins Ray, a native of Wilkesboro, North Carolina.
  • According to her family, Mrs. Ray was a loving, devoted mother and a devout Christian who delighted in her children.

Bode Technology Awarded NIJ Research and Development Grant to Advance Investigative Genetic Genealogy

Retrieved on: 
Monday, December 19, 2022

LORTON, Va., Dec. 19, 2022 /PRNewswire-PRWeb/ -- Bode Technology announced that it has been awarded a $437K grant (15PNIJ-21-GG-04143-MUMU) from the National Institute of Justice (NIJ) under the Research and Development in Forensic Science for Criminal Justice Purposes grant program to address pressing research in the groundbreaking field of Investigative Genetic Genealogy (IGG) that enables law enforcement to solve more cold cases.

Key Points: 
  • Bode Technology announced that it has been awarded a $437K grant (15PNIJ-21-GG-04143-MUMU) from the National Institute of Justice (NIJ) under the Research and Development in Forensic Science for Criminal Justice Purposes grant program to address pressing research in the groundbreaking field of Investigative Genetic Genealogy (IGG) that enables law enforcement to solve more cold cases.
  • LORTON, Va., Dec. 19, 2022 /PRNewswire-PRWeb/ -- Bode Technology announced that it has been awarded a $437K grant (15PNIJ-21-GG-04143-MUMU) from the National Institute of Justice (NIJ) under the Research and Development in Forensic Science for Criminal Justice Purposes grant program to address pressing research in the groundbreaking field of Investigative Genetic Genealogy (IGG) that enables law enforcement to solve more cold cases.
  • Investigative Genetic Genealogy is increasingly being used to uncover new investigative leads on cold cases.
  • "Investigative Genetic Genealogy has proven to be one of the most powerful new forensic techniques of the past decade.

LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare Cardiovascular Diseases

Retrieved on: 
Wednesday, July 21, 2021

NEW YORK, July 21, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, today announced that it has acquired Stelios Therapeutics, an early-stage company developing novel adeno-associated virus (AAV)-mediated gene therapies for rare genetic cardiac conditions. Through the agreement, LEXEO obtains exclusive rights to three preclinical AAV-mediated gene therapy programs focused on TNNI3-associated hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC), two rare cardiac disorders with no approved pharmacological treatments and significant commercial potential. Stelios’ Scientific Co-founder and Professor of Medicine in Cardiology at the University of California San Diego School of Medicine (UC San Diego), Dr. Eric Adler, will assist in cardiovascular research efforts at LEXEO Therapeutics.

Key Points: 
  • The acquisition allows LEXEO to expand its pipeline in rare genetic cardiac diseases with the addition of three novel programs.
  • The Stelios programs complement and broaden LEXEOs advanced pre-clinical gene therapy pipeline in rare cardiac diseases, which currently includes LX2006, an IV-administered, AAV-mediated gene therapy program for the potential treatment of cardiomyopathy associated with Friedreichs ataxia (FA).
  • LEXEO and Stelios share the same commitment to advancing therapies for patients with rare cardiac diseases.
  • Dr. Adler commented, Despite recent medical advancements in the rare cardiovascular field, many rare cardiac diseases remain underdiagnosed and undertreated.

M6P Therapeutics Announces Presentation at the Upcoming 16th International Symposium of MPS and Related Diseases

Retrieved on: 
Wednesday, July 21, 2021

M6P Therapeutics (M6PT or the Company), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), announced today its participation at the 16th International Symposium of MPS and Related Diseases, a research conference dedicated to the exchange of knowledge on mucopolysaccharidoses (MPS) and related syndromes, taking place virtually July 23-25, 2021.

Key Points: 
  • M6P Therapeutics (M6PT or the Company), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), announced today its participation at the 16th International Symposium of MPS and Related Diseases, a research conference dedicated to the exchange of knowledge on mucopolysaccharidoses (MPS) and related syndromes, taking place virtually July 23-25, 2021.
  • Details related to M6PTs oral presentation at MPS 2021 are below:
    M6P Therapeutics is a privately held, venture-backed biotechnology company developing the next-generation of targeted recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs).
  • This can potentially lead to more efficacious treatments with lower therapy burden, as well as new therapies for currently untreated diseases.
  • M6P Therapeutics mission is to translate advanced science into best-in-class therapies that address unmet needs within the LSD community.

Survey Finds People with Sickle Cell Disease Report Vastly Different Experiences with HCPs, Emergency Departments

Retrieved on: 
Thursday, July 1, 2021

The inaugural Sickle Cell Disease In America survey illuminates the perspectives and experiences of people living with sickle cell disease.

Key Points: 
  • The inaugural Sickle Cell Disease In America survey illuminates the perspectives and experiences of people living with sickle cell disease.
  • In fact, 92% of Sickle Cell Disease In America respondents said they see a hematologist for their sickle cell disease, while eight in 10 respondents said a hematologist is the primary HCP managing their condition.
  • As a result of these experiences, people with sickle cell disease might end up avoiding going to the emergency department, making access to care increasingly difficult.
  • The Sickle Cell Disease In America survey, which fielded from Oct. 19, 2020 to Feb. 26, 2021, included responses from 111 people living with sickle cell disease.

Global Data Center Migration Market Report 2021-2026: Mergers and Acquisitions, Regulatory Requirements, and End of Lease Requirements

Retrieved on: 
Thursday, June 24, 2021

The data center migration is done due to a variety of reasons including mergers and acquisitions, regulatory requirements, and end of lease requirements.

Key Points: 
  • The data center migration is done due to a variety of reasons including mergers and acquisitions, regulatory requirements, and end of lease requirements.
  • The data center migration provides significant cost savings to the organization, which is one of the major factors anticipated to propel the growth of the data center migration market during the forecast period.
  • Datacenter migration provides better security and improved efficiency, which is leading to many companies undergoing data center migration and is anticipated to boost the data center migration market growth during the forecast period.
  • The recent outbreak of the novel coronavirus disease had a positive impact on the data center migration market.

Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease

Retrieved on: 
Wednesday, June 23, 2021

The proceeds of the financing will be used to advance Glycomines lead drug candidate, GLM101, through initial clinical trials in patients.

Key Points: 
  • The proceeds of the financing will be used to advance Glycomines lead drug candidate, GLM101, through initial clinical trials in patients.
  • GLM101 is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
  • The Series B financing includes $35 million of new funds in addition to the $33 million announced in August 2019.
  • In addition, all previous Series B investors Novo Holdings A/S, Asahi Kasei Pharma Ventures, Mission BioCapital, Sanderling Ventures, and Chiesi Ventures participated.

CPABC: Northwest B.C.’s growing population and strong demand pushing housing costs to new highs

Retrieved on: 
Wednesday, June 16, 2021

In 2020, the regions population growth came from a fairly even mix of international migrants, interprovincial migrants, and natural growth (births minus mortalities).

Key Points: 
  • In 2020, the regions population growth came from a fairly even mix of international migrants, interprovincial migrants, and natural growth (births minus mortalities).
  • However, the pace of population growth was moderated by an outflow of 265 residents relocating to other parts in the province.
  • Going forward, we will need to attract more migrants to support our growing economy and aging population.
  • A growing population also means increasing demand for housing, and supply has not kept up.

1972 'Beyond Hope' Homicide Solved in 2 Hours Using Forensic Genetic Genealogy

Retrieved on: 
Friday, June 4, 2021

In November 2020, the Naperville Police Department contacted Identifinders International to try to solve the case using forensic genetic genealogy as a last resort.

Key Points: 
  • In November 2020, the Naperville Police Department contacted Identifinders International to try to solve the case using forensic genetic genealogy as a last resort.
  • Over the next six months, Identifinders faced numerous challenges in creating viable genetic genealogy data without a guarantee of success.
  • Yet once that data was uploaded to the genetic genealogy database GEDMatch, the case was solved in only two hours.
  • Identifinders International is an award-winning pioneer in the application of forensic genetic genealogy Y-DNA and autosomal SNP analysis to cold case homicides, sexual assaults, and Baby and Child Doe cases.

 Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo

Retrieved on: 
Tuesday, June 1, 2021

Additionally, both mutant and wild-type mtDNA can co-exist within the mitochondria of a cell, a phenomenon called mtDNA heteroplasmy.

Key Points: 
  • Additionally, both mutant and wild-type mtDNA can co-exist within the mitochondria of a cell, a phenomenon called mtDNA heteroplasmy.
  • When specific threshold levels of mutant mtDNA are reached, cell function can be compromised, and disease can manifest1.
  • In this study, a mitochondrial-targeted ARCUS nuclease (mitoARCUS) used to edit mutant mtDNA was particularly effective, in part because of the nucleases small size and single protein nature.
  • Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS genome editing platform.